Navigation Links
Drug Shields Mice From Emphysema
Date:12/22/2008

Experimental approach seemed to protect the animals from smoke's harmful effects, researchers say

MONDAY, Dec. 22 (HealthDay News) -- In experiments in mice, scientists have shown that a new drug may protect the animals from the respiratory damage caused by cigarettes.

The finding holds out hope for patients with chronic obstructive pulmonary disease (COPD) -- a chronic progressive lung disease involving both emphysema and chronic obstructive bronchitis.

COPD, most commonly linked to smoking, is the fourth leading cause of death in the United States and there are no effective treatments.

"Our previous studies have shown that there is a defect in Nrf2 -- a master regulator of antioxidant and detoxifying pathways -- in the lungs of COPD patients that may be involved in the severity of this disease," explained lead researcher Shyam Biswal, an associate professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

In this study, the researchers used a novel drug molecule called CDDO-imidazole (CDDO-Im) to curb the progression of the disease by targeting the Nrf2 pathway.

"The result demonstrates that this strategy is effective in the preclinical model of emphysema," Biswal said.

The report is published in this week's online edition of the Proceedings of the National Academy of Sciences.

For the study, Biswal's team exposed mice to cigarette smoke for six months. Half the mice were treated with CDDO-Im while the other animals were not.

The researchers found that mice treated with CDDO-Im did not develop heart and lung damage while their untreated counterparts did.

Dr. Norman Edelman, chief medical officer of the American Lung Association, believes the new approach to treating COPD could be effective.

"There have been several studies identifying disrupted oxidant defense systems in COPD," Edelman said. "What's different about this one is that a control point for a whole group of oxidant defenses has been identified in rather elegant studies. Thus, if a therapy up-regulating this site were developed it would be more likely to be effective in COPD," he said.

This study provides hope that strategies aimed at targeting the Nrf2 pathway might be effective in inhibiting the development of emphysema, Biswal said.

"Future studies will be done in COPD patients to test the strategy of targeting Nrf2, to test the efficacy in reducing the burden of this debilitating disease," Biswal said.

However, Dr. Bartolome R. Celli, chief of pulmonary care at St. Elizabeth's Medical Center in Boston, said the jury is still out on the effectiveness of this approach.

"It is an interesting and intriguing study," Celli said. "However, from the experiments in mice to reality in humans there usually is a great distance," he said.

There is consensus that oxidative stress associated with cigarette smoking is important in COPD, so balancing oxidative stress with antioxidants makes sense, Celli said.

"This study takes it one step further by testing the hypothesis in vivo [animals]," according to Celli. "Let's wait for the translation into humans," he said.

More information

For more information on emphysema, visit the U.S. National Library of Medicine .



SOURCES: Shyam Biswal, Ph.D., associate professor, Johns Hopkins Bloomberg School of Public Health, Baltimore; Bartolome R. Celli, M.D., chief, pulmonary care, St. Elizabeth's Medical Center, Boston; Norman Edelman, M.D., chief medical officer, American Lung Association; Dec. 22-26, 2008, Proceedings of the National Academy of Sciences, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football helmet shields can protect against a kick in the face
2. Col. Robert E. Shields Joins Palmetto GBAs Board of Directors
3. Appropriate timing in the use of breast shields in children can further reduce MDCT radiation dose
4. Potential treatment option for severe emphysema under study
5. Young Pop Stars Emphysema Startles Experts
6. Acne Drug Prevents Tissue Damage From Emphysema
7. Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
8. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
9. New York Methodist Hospital to study airway bypass treatment for emphysema
10. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
11. Lung Bypass Could Fight Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Shields Mice From Emphysema
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Calif. (PRWEB) , ... March 24, 2017 , ... ... raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... instant demand for the product – with nearly 2,000 consumers (and counting) already ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/27/2017)... HAMILTON, N.J. , March 27, 2017 ... company and leading in vivo pharmacology contract ... Solar Farm adjacent to its newly expanded preclinical research ... The solar farm provides a cleaner, renewable energy source ... on the environment. Completion of the Genesis Solar Farm ...
(Date:3/24/2017)... , March 24, 2017 According to a new report ... and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 ... at a CAGR of 3.6% during the forecast period. ... ... Research Logo ...
Breaking Medicine Technology: